PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32349283-0 2020 Fingolimod Modulates Dendritic Architecture in a BDNF-Dependent Manner. Fingolimod Hydrochloride 0-10 brain derived neurotrophic factor Mus musculus 49-53 32349283-3 2020 Among the different therapeutic strategies developed to improve endogenous BDNF levels is the administration of the BDNF-inducing drug Fingolimod, an agonist of the sphingosine-1-phosphate receptor. Fingolimod Hydrochloride 135-145 brain derived neurotrophic factor Mus musculus 75-79 32349283-3 2020 Among the different therapeutic strategies developed to improve endogenous BDNF levels is the administration of the BDNF-inducing drug Fingolimod, an agonist of the sphingosine-1-phosphate receptor. Fingolimod Hydrochloride 135-145 brain derived neurotrophic factor Mus musculus 116-120 32349283-5 2020 However, the cellular mechanisms through which Fingolimod mediates its BDNF-dependent therapeutic effects remain unclear. Fingolimod Hydrochloride 47-57 brain derived neurotrophic factor Mus musculus 71-75 32349283-8 2020 Importantly, we show that BDNF release is required for these actions of Fingolimod. Fingolimod Hydrochloride 72-82 brain derived neurotrophic factor Mus musculus 26-30 32349283-11 2020 Our study provides insights into understanding the BDNF-dependent therapeutic actions of Fingolimod. Fingolimod Hydrochloride 89-99 brain derived neurotrophic factor Mus musculus 51-55 31129200-0 2019 FTY720 Improves Behavior, Increases Brain Derived Neurotrophic Factor Levels and Reduces alpha-Synuclein Pathology in Parkinsonian GM2+/- Mice. Fingolimod Hydrochloride 0-6 brain derived neurotrophic factor Mus musculus 36-69 31751571-6 2020 Our prior studies using the parent compound FTY720, a food and drug administration (FDA) approved immunosuppressive for multiple sclerosis, reveal that FTY720 protects parkinsonian mice by increasing BDNF. Fingolimod Hydrochloride 44-50 brain derived neurotrophic factor Mus musculus 200-204 29804232-7 2019 Moreover, we confirmed the contribution of the proper balance of BDNF/TrkB/p75NTR on HD pathology by a pharmacological approach using fingolimod. Fingolimod Hydrochloride 134-144 brain derived neurotrophic factor Mus musculus 65-69 27439747-6 2017 To increase BDNF, we use a novel strategy, repeated intraperitoneal injections of fingolimod (Gilenya). Fingolimod Hydrochloride 82-92 brain derived neurotrophic factor Mus musculus 12-16 30152864-16 2018 We did find an increase of BDNF protein after a single injection of fingolimod 0.1 or 1.0 mg/kg, but not after multiple injections, indicating that the BDNF response to fingolimod is unsustainable over time. Fingolimod Hydrochloride 68-78 brain derived neurotrophic factor Mus musculus 27-31 30152864-16 2018 We did find an increase of BDNF protein after a single injection of fingolimod 0.1 or 1.0 mg/kg, but not after multiple injections, indicating that the BDNF response to fingolimod is unsustainable over time. Fingolimod Hydrochloride 169-179 brain derived neurotrophic factor Mus musculus 152-156 29530550-0 2018 Fingolimod inhibits brain atrophy and promotes brain-derived neurotrophic factor in an animal model of multiple sclerosis. Fingolimod Hydrochloride 0-10 brain derived neurotrophic factor Mus musculus 47-80 29530550-6 2018 Fingolimod-dependent tissue preservation was associated with induction of BDNF specifically within the brain and co-localized with neuronal soma. Fingolimod Hydrochloride 0-10 brain derived neurotrophic factor Mus musculus 74-78 29530550-9 2018 Fingolimod-mediated BDNF increases within the CNS may contribute to limiting progressive tissue loss during chronic neuroinflammation. Fingolimod Hydrochloride 0-10 brain derived neurotrophic factor Mus musculus 20-24 22891354-0 2012 Fingolimod, a sphingosine-1 phosphate receptor modulator, increases BDNF levels and improves symptoms of a mouse model of Rett syndrome. Fingolimod Hydrochloride 0-10 brain derived neurotrophic factor Mus musculus 68-72 27456702-7 2016 The beneficial effect of fingolimod administration was associated with a significant modulation of neuroinflammatory and protective genes (CD11b, Foxp3, iNOS, Il1beta, Il10, Arg1, and Bdnf) in motor cortex and spinal cord of animals. Fingolimod Hydrochloride 25-35 brain derived neurotrophic factor Mus musculus 184-188 27528608-0 2016 FTY720/Fingolimod Reduces Synucleinopathy and Improves Gut Motility in A53T Mice: CONTRIBUTIONS OF PRO-BRAIN-DERIVED NEUROTROPHIC FACTOR (PRO-BDNF) AND MATURE BDNF. Fingolimod Hydrochloride 0-6 brain derived neurotrophic factor Mus musculus 142-146 27528608-0 2016 FTY720/Fingolimod Reduces Synucleinopathy and Improves Gut Motility in A53T Mice: CONTRIBUTIONS OF PRO-BRAIN-DERIVED NEUROTROPHIC FACTOR (PRO-BDNF) AND MATURE BDNF. Fingolimod Hydrochloride 0-6 brain derived neurotrophic factor Mus musculus 159-163 27528608-0 2016 FTY720/Fingolimod Reduces Synucleinopathy and Improves Gut Motility in A53T Mice: CONTRIBUTIONS OF PRO-BRAIN-DERIVED NEUROTROPHIC FACTOR (PRO-BDNF) AND MATURE BDNF. Fingolimod Hydrochloride 7-17 brain derived neurotrophic factor Mus musculus 142-146 27528608-0 2016 FTY720/Fingolimod Reduces Synucleinopathy and Improves Gut Motility in A53T Mice: CONTRIBUTIONS OF PRO-BRAIN-DERIVED NEUROTROPHIC FACTOR (PRO-BDNF) AND MATURE BDNF. Fingolimod Hydrochloride 7-17 brain derived neurotrophic factor Mus musculus 159-163 26171219-1 2015 Recent findings indicate that fingolimod, the first oral drug approved for the treatment of multiple sclerosis (MS), acts as a direct inhibitor of histone deacetylases (HDACs) and enhances the production of brain-derived neurotrophic factor (BDNF) in the CNS. Fingolimod Hydrochloride 30-40 brain derived neurotrophic factor Mus musculus 207-240 26171219-1 2015 Recent findings indicate that fingolimod, the first oral drug approved for the treatment of multiple sclerosis (MS), acts as a direct inhibitor of histone deacetylases (HDACs) and enhances the production of brain-derived neurotrophic factor (BDNF) in the CNS. Fingolimod Hydrochloride 30-40 brain derived neurotrophic factor Mus musculus 242-246 22891354-6 2012 Ongoing synaptic activity and MAPK signaling is required for fingolimod-induced BDNF increase, a pathway that can also be activated in vivo by systemic fingolimod administration. Fingolimod Hydrochloride 61-71 brain derived neurotrophic factor Mus musculus 80-84 22891354-6 2012 Ongoing synaptic activity and MAPK signaling is required for fingolimod-induced BDNF increase, a pathway that can also be activated in vivo by systemic fingolimod administration. Fingolimod Hydrochloride 152-162 brain derived neurotrophic factor Mus musculus 80-84 26063761-4 2015 Fingolimod (FTY720), a modulator of sphingosine-1 phosphate (S1P) receptors, has been shown to increase BDNF levels and to reduce astrogliosis, proving its potential to regulate trophic support and inflammatory response. Fingolimod Hydrochloride 0-10 brain derived neurotrophic factor Mus musculus 104-108 26063761-4 2015 Fingolimod (FTY720), a modulator of sphingosine-1 phosphate (S1P) receptors, has been shown to increase BDNF levels and to reduce astrogliosis, proving its potential to regulate trophic support and inflammatory response. Fingolimod Hydrochloride 12-18 brain derived neurotrophic factor Mus musculus 104-108 22891354-5 2012 In cultured neurons, fingolimod increases BDNF levels and counteracts NMDA-induced neuronal death in a BDNF-dependent manner. Fingolimod Hydrochloride 21-31 brain derived neurotrophic factor Mus musculus 42-46 22891354-5 2012 In cultured neurons, fingolimod increases BDNF levels and counteracts NMDA-induced neuronal death in a BDNF-dependent manner. Fingolimod Hydrochloride 21-31 brain derived neurotrophic factor Mus musculus 103-107